MapLight is a high-risk, high-upside CNS biotech where one schizophrenia readout could determine whether ML-007C-MA becomes a best-in-class muscarinic challenger or the company resets to early-stage pipeline value.
Overview
MapLight Therapeutics is a pre-revenue clinical-stage CNS biotech pursuing circuit-specific therapies for neuropsychiatric disorders. Its lead candidate, ML-007C-MA, is in Phase 2 trials for schizophrenia and Alzheimer’s disease psychosis, with schizophrenia data expected by mid-August 2026. The investment case is highly binary: positive data could validate a best-in-class muscarinic therapy competing with BMS’s Cobenfy, while failure would sharply impair value. A strong cash runway through 2027 supports near-term execution, but commercialization remains years away.